Cargando…
Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
Alpha synuclein has a key role in the pathogenesis of Parkinson’s disease (PD), Dementia with Lewy Bodies (LBD) and Multiple System Atrophy (MSA). Immunotherapies aiming at neutralising toxic αSyn species are being investigated in the clinic as potential disease modifying therapies for PD and other...
Autores principales: | Nimmo, Jacqui T., Smith, Harry, Wang, Chang Yi, Teeling, Jessica L., Nicoll, James A. R., Verma, Ajay, Dodart, Jean-Cosme, Liu, Zhi, Lin, Feng, Carare, Roxana O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732825/ https://www.ncbi.nlm.nih.gov/pubmed/34741635 http://dx.doi.org/10.1007/s00401-021-02381-5 |
Ejemplares similares
-
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
por: Nimmo, Jacqui Taryn, et al.
Publicado: (2021) -
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
por: Nimmo, Jacqui T., et al.
Publicado: (2020) -
Correction: Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
por: Nimmo, Jacqui T., et al.
Publicado: (2023) -
A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine
por: Yu, Hui Jing, et al.
Publicado: (2022) -
Peri‐arterial pathways for clearance of α‐Synuclein and tau from the brain: Implications for the pathogenesis of dementias and for immunotherapy
por: Nimmo, Jacqui, et al.
Publicado: (2020)